What is the Windlas Biotech PE ratio today?
Windlas Biotech's PE ratio is 28.7 at the 29 October 2026 close (₹923.40 a share): a market capitalisation of ₹1,906 crore divided by standalone net profit of ₹66.4 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹66.4 crore) it is 28.7.
What is the Windlas Biotech debt to equity ratio?
Windlas Biotech's debt-to-equity ratio was 0.05 on 31 March 2026: borrowings of ₹29.9 crore against total equity of ₹581 crore. A year earlier, on 31 March 2025, it was 0.05.
What is the Windlas Biotech net worth?
Windlas Biotech's net worth — shareholders' equity in its standalone balance sheet — was ₹581 crore on 31 March 2026, up 14.8% from ₹506 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹1,906 crore at the 29 October 2026 close.
What is the Windlas Biotech PB ratio (price to book value)?
Windlas Biotech's price-to-book (PB) ratio is 3.28 at the 29 October 2026 close: a market capitalisation of ₹1,906 crore divided by shareholders' equity (book value) of ₹581 crore on 31 March 2026. That is a book value of ₹281.47 per share against a share price of ₹923.40.
What is the Windlas Biotech ROE and ROCE?
In FY26, Windlas Biotech's return on equity (ROE) was 12.2% and its return on capital employed (ROCE) was 13.5%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 12.7% and ROCE 13.7%.
What is the Windlas Biotech book value per share?
Windlas Biotech's book value per share was ₹281.47 on 31 March 2026: shareholders' equity of ₹581 crore divided by the 2.06 crore shares in issue, up 16.6% from ₹241.31 a year earlier. The share price at the 29 October 2026 close was ₹923.40.
What is the Windlas Biotech market cap?
Windlas Biotech's market capitalisation was ₹1,906 crore at the 29 October 2026 close: 2.06 crore shares at ₹923.40 each.
What is the Windlas Biotech EPS?
Windlas Biotech's basic earnings per share (EPS) were ₹31.59 in FY26, against ₹29.03 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹31.63.
What is the Windlas Biotech dividend in 2026 and its record date?
In 2026, Windlas Biotech has declared one dividend: ₹6.30 with record date 16 July 2026.
Is Windlas Biotech debt free?
No. Windlas Biotech had borrowings of ₹29.9 crore on 31 March 2026 (standalone balance sheet), a debt-to-equity ratio of 0.05. Its cash and current investments were ₹270 crore, so it held net cash of ₹240 crore.
What is the Windlas Biotech promoter holding?
Promoters held 63.31% of Windlas Biotech on 30 September 2026, unchanged from the previous quarter and up 1.32 percentage points from 61.99% a year earlier, according to the shareholding pattern filed with NSE.
When are the Windlas Biotech next results?
Windlas Biotech has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.
What is the Windlas Biotech dividend yield?
Windlas Biotech's dividend yield is 0.68% at the 29 October 2026 close: dividends of ₹6.30 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹923.40. They were ₹6.30 on 16 July 2026.
What is the Windlas Biotech free cash flow?
In FY26, Windlas Biotech generated ₹105 crore of cash from operations and spent ₹67.7 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹37.3 crore. In FY25 it was ₹16 crore.
What are the Windlas Biotech latest quarterly results?
Windlas Biotech's latest results are for Q1 FY27 (April–June 2026), filed on 10 August 2026: standalone net profit ₹17.7 crore, down 0.1% from ₹17.7 crore in Q1 FY26; revenue from operations ₹248 crore, up 18.1% year on year.
What is the Windlas Biotech shareholding pattern?
On 30 September 2026, Windlas Biotech's shares were held by promoters 63.31%, foreign portfolio investors (FII/FPI) 2.08%, domestic institutions (DII) 7.24% (including mutual funds at 3.10%) and retail and other non-institutional investors 27.36%. Over the year, FII holding was up 0.97 percentage points from 1.11% and DII holding was down 4.19 percentage points from 11.43%.
What is the Windlas Biotech revenue and profit in FY26?
In FY26 (April 2025–March 2026), Windlas Biotech's standalone net profit was ₹66.4 crore, up 9.5% from ₹60.6 crore in FY25, on revenue from operations of ₹904 crore (up 19.0%). Over three years, from FY23, net profit was up 55.8%.
How does Windlas Biotech compare with its peers?
On FY26 standalone figures, against Hester Biosciences, Indoco Remedies and Sai Parenterals: Windlas Biotech's operating margin of 8.2% is the third highest of the four (Hester Biosciences 21.3%, Indoco Remedies 3.0%, Sai Parenterals 15.3%; peer average 13.2%); its return on equity of 12.2% is the second highest of the four (Hester Biosciences 14.4%, Indoco Remedies −0.5%, Sai Parenterals 3.5%; peer average 5.8%).
Windlas Biotech vs Hester Biosciences: how do they compare?
In FY26, Windlas Biotech earned net profit of ₹66.4 crore on revenue of ₹904 crore, against ₹52.1 crore on ₹292 crore for Hester Biosciences. Windlas Biotech's operating margin was 8.2% (Hester Biosciences 21.3%) and its return on equity 12.2% (Hester Biosciences 14.4%). At the 29 October 2026 close, Windlas Biotech's market capitalisation was ₹1,906 crore against ₹1,963 crore for Hester Biosciences, and its PE ratio on FY26 profit 28.7 against 37.7.
Standalone figures from the company's filings with NSE; prices are NSE closing prices.
